Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403455 · ClinicalTrials.gov registry record · Phase 3
Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
NCT00403455: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT00403455 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00403455, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
Study Summary
Dr. Wang's merit review is aimed at providing a better understanding of the relationship between SLC6A3/SLC6A4 and the mental health of veterans exposed to high levels of combat stress, specifically focusing on PTSD symptoms, related co-morbidities, treatment outcomes and seeks new approaches to therapy for our Veteran population.
Interventions
- DRUG Paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403455
The ClinicalTrials.gov registry entry for NCT00403455 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paroxetine is the first listed.
NCT00403455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403455 about?
NCT00403455 is a clinical study titled "Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities". Dr. Wang's merit review is aimed at providing a better understanding of the relationship between SLC6A3/SLC6A4 and the mental health of veterans exposed to high levels of combat stress, specifically focusing on PTSD symptoms, related co-morbidities, treatment outcomes and seeks new approaches to the...
What is the current status of trial NCT00403455?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2006-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00403455?
The interventions under investigation include: Paroxetine (DRUG).
Who is sponsoring clinical trial NCT00403455?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.